Roche advances skin cancer trials as part of combination therapy strategy

Roche is pressing ahead with two skin cancer trials that combine its immunotherapy Tecentriq with other drugs after early data showed the treatments were well-tolerated and effective in a small number of patients, treatment the company said Monday.

One study combined Tecentriq with Cotellic and Zelboraf in 30 patients with untreated BRAFV600 mutation-positive metastatic melanoma, price the other Tecentriq with Cotellic for 10 patients with BRAF-wild-type and BRAF-mutant metastatic melanoma.

Read Full Article Here >>